Thomas P. C. Dorlo

4.1k citations

105 papers · 2.6k indexed · 1 hit paper · h-index 26

Public Health, Environmental and Occupational Health top 0.5%
- Research on Leishmaniasis Studies 46
- Acute Lymphoblastic Leukemia research 7
Parasitology top 1%
- Parasites and Host Interactions 15
Epidemiology top 2%
- Trypanosoma species research and implications 30
Organic Chemistry top 5%
- Synthesis and Biological Evaluation 13
Infectious Diseases top 10%
Pharmacology
- Pharmacogenetics and Drug Metabolism 14
- Antibiotics Pharmacokinetics and Efficacy 9
Oncology
- Cancer Treatment and Pharmacology 7

Co-authors: Jos H. Beijnen Peter J. de Vries Manica Balasegaram Alwin D. R. Huitema Anke E Kip Jan H.M. Schellens Suman Rijal Marleen Boelaert
Cited by: Public Health, Environmental and Occupational Health Parasitology Epidemiology
Journals: Journal of Biological Chemistry (1 paper)PLoS ONE (1 paper)Clinical Infectious Diseases (3 papers)
Partner nations: Netherlands Sweden Switzerland

In The Last Decade

Thomas P. C. Dorlo

98 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Thomas P. C. Dorlo

Since Specialization

Citations

This map shows the geographic impact of Thomas P. C. Dorlo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas P. C. Dorlo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas P. C. Dorlo more than expected).

Fields of papers citing papers by Thomas P. C. Dorlo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas P. C. Dorlo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas P. C. Dorlo. The network helps show where Thomas P. C. Dorlo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas P. C. Dorlo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas P. C. Dorlo Line = papers co-authored together Thomas P. C. Dorlo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Does one model fit all mAbs? An evaluation of population pharmacokinetic models mAbs ·Stefan Berg,Philine E. A. Adolfsen,Thomas P. C. Dorlo,Theo Rispens	2025	0
2	Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices Journal of Chromatography B ·Wietse M. Schouten,Katrien Van Bocxlaer,Hilde Rosing,Alwin D. R. Huitema,Jos H. Beijnen,Jadel M. Kratz,Charles E. Mowbray,Thomas P. C. Dorlo	2024	0
3	Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach Antimicrobial Agents and Chemotherapy ·Bhargavi Srija Ramisetty,Sihyung Yang,Thomas P. C. Dorlo,Michael Zhuo Wang	2024	0
4	Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa The Journal of Infectious Diseases ·Wan‐Yu Chu,Luka Verrest,Brima M. Younis,Ahmed Musa,Jane Mbui,Rezika Mohammed,Joseph Olobo,Koert Ritmeijer,Séverine Monnerat,Monique Wasunna,Ignace C. Roseboom,Alexandra Solomos,Alwin D. R. Huitema,Fabiana Alves,Thomas P. C. Dorlo	2024	1
5	Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models Drug Metabolism and Disposition ·David Damoiseaux,Jos H. Beijnen,Alwin D. R. Huitema,Thomas P. C. Dorlo	2024	0
6	The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib Clinical and Translational Science ·Lisa T. van der Heijden,Neeltje Steeghs,Jos H. Beijnen,Alwin D. R. Huitema,Thomas P. C. Dorlo	2023	2
7	Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs Clinical Pharmacokinetics ·Julie M. Janssen,David Damoiseaux,J. G. Coen van Hasselt,Frédéric Amant,Kristel Van Calsteren,Jos H. Beijnen,Alwin D. R. Huitema,Thomas P. C. Dorlo	2023	1
8	Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk CPT Pharmacometrics & Systems Pharmacology ·David Damoiseaux,Frédéric Amant,Jos H. Beijnen,S. Barnett,Gareth J. Veal,Alwin D. R. Huitema,Thomas P. C. Dorlo	2023	5
9	Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling CPT Pharmacometrics & Systems Pharmacology ·Simon E. Koele,Thomas P. C. Dorlo,Caryn M. Upton,Rob E. Aarnoutse,Elin M. Svensson	2023	1
10	Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis Clinical and Translational Science ·David Damoiseaux,Alfred H. Schinkel,Jos H. Beijnen,Alwin D. R. Huitema,Thomas P. C. Dorlo	2023	1
11	A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients EJNMMI Research ·Hinke Siebinga,Berlinda J. de Wit–van der Veen,Jos H. Beijnen,Thomas P. C. Dorlo,Alwin D. R. Huitema,Jeroen J. M. A. Hendrikx	2023	4
12	Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs Biomedical Chromatography ·Ignace C. Roseboom,Hilde Rosing,Jos H. Beijnen,Thomas P. C. Dorlo	2022	0
13	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics Cancer Medicine ·Laura Molenaar‐Kuijsten,Bart Jacobs,Sophie A. Kurk,Anne M. May,Thomas P. C. Dorlo,Jacob Hendrik Beijnen,Neeltje Steeghs,Alwin Dagmar Redmar Huitema	2021	6
14	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study Pharmaceutical Research ·Marie‐Rose B. S. Crombag,Thomas P. C. Dorlo,Ellen van der Pan,Anoek van Straten,Andries M. Bergman,Nielka P. van Erp,Jos H. Beijnen,Alwin D. R. Huitema	2019	6
15	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes Blood Advances ·Jurgen Langenhorst,Charlotte van Kesteren,Erik M. van Maarseveen,Thomas P. C. Dorlo,Stefan Nierkens,Caroline A. Lindemans,Moniek A. de Witte,Anna van Rhenen,Reinier A. P. Raijmakers,Marc Bierings,Jürgen Kuball,Alwin D. R. Huitema,Jaap Jan Boelens	2019	45
16	Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel? Pharmaceutical Research ·Marie‐Rose B. S. Crombag,Stijn L.W. Koolen,Sophie Wijngaard,Markus Joerger,Thomas P. C. Dorlo,Nielka P. van Erp,Ron H.J. Mathijssen,Jos H. Beijnen,Alwin D. R. Huitema	2019	5
17	Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study Pharmaceutical Research ·Marie‐Rose B. S. Crombag,Aurelia H. M. de Vries Schultink,Stijn L.W. Koolen,Sophie Wijngaard,Markus Joerger,Jan H.M. Schellens,Thomas P. C. Dorlo,Nielka P. van Erp,Ron H.J. Mathijssen,Jos H. Beijnen,Alwin D. R. Huitema	2019	10
18	Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance Clinical Infectious Diseases ·Suman Rijal,Bart Ostyn,Surendra Uranw,Keshav Rai,Narayan Raj Bhattarai,Thomas P. C. Dorlo,Jos H. Beijnen,Manu Vanaerschot,Saskia Decuypere,Subodh Sagar Dhakal,Murari Lal Das,Prahlad Karki,Rupa Rajbhandari Singh,Marleen Boelaert,Jean‐Claude Dujardin	2013	236
19	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisbreakdown → Journal of Antimicrobial Chemotherapy ·Thomas P. C. Dorlo,Manica Balasegaram,Jos H. Beijnen,Peter J. de Vries	2012	573
20	Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients Antimicrobial Agents and Chemotherapy ·Thomas P. C. Dorlo,P. P. A. M. van Thiel,Alwin D. R. Huitema,Ron J. Keizer,Henry J.C. de Vries,Jos H. Beijnen,Peter J. de Vries	2008	118

About Thomas P. C. Dorlo

Thomas P. C. Dorlo is a scholar working on Parasitology, Public Health, Environmental and Occupational Health and Pharmacology, having authored 105 papers that have together received 2.6k indexed citations. Recurring topics across this work include Research on Leishmaniasis Studies (46 papers), Trypanosoma species research and implications (30 papers), Parasites and Host Interactions (15 papers), Pharmacogenetics and Drug Metabolism (14 papers), Synthesis and Biological Evaluation (13 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers), Cancer Treatment and Pharmacology (7 papers) and Acute Lymphoblastic Leukemia research (7 papers). The work is most often cited by research in Public Health, Environmental and Occupational Health (1.8k citations), Parasitology (372 citations) and Epidemiology (1.1k citations). Thomas P. C. Dorlo has collaborated with scholars based in Netherlands, Sweden and Switzerland. Frequent co-authors include Jos H. Beijnen, Peter J. de Vries, Manica Balasegaram, Alwin D. R. Huitema, Anke E Kip, Jan H.M. Schellens, Suman Rijal, Marleen Boelaert, Bart Ostyn and Jean‐Claude Dujardin. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact